Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights a commitment to AI-driven innovation and financial discipline, which are positives, but lacks specific financial details such as revenue or margin figures. The Q&A section does not provide additional insights, and risks related to AI development and regulatory compliance are noted. With a market cap of approximately $1.8 billion, the absence of explicit financial metrics and shareholder return plans suggests a neutral stock price movement in the short term.
Key Financial Performance
Revenue Not explicitly mentioned in the provided text.
Margins Not explicitly mentioned in the provided text.
Cash Flow Not explicitly mentioned in the provided text.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-driven product engine: The company is evolving its platform into a repeatable, AI-driven product engine to create valuable products.
Financial discipline: The company is committed to financial discipline and thoughtful capital allocation, focusing on data-driven prioritization of high-conviction opportunities.
AI integration: The company is focusing on leveraging AI to create better medicines, emphasizing proof points in wholly owned and partner programs to demonstrate AI's value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
AI-driven product engine: The company is focusing on evolving its platform into a repeatable, AI-driven product engine. This involves risks related to technological development and execution, as the success of this strategy depends on the ability to effectively harness AI to create valuable products. Failure to do so could impact the company's operations and strategic objectives.
Financial discipline and capital allocation: There is a strong commitment to financial discipline and thoughtful capital allocation. Risks include the potential for misallocation of resources or failure to prioritize high-conviction opportunities, which could adversely affect the company's financial health and ability to deliver durable value.
Regulatory compliance: The mention of forward-looking statements and SEC filings implies regulatory compliance risks. Non-compliance with regulatory requirements could lead to legal challenges and impact the company's operations and reputation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
AI-driven product engine: Evolving the platform into a repeatable, AI-driven product engine to create products of value.
Financial discipline: Strong commitment to financial discipline and thoughtful capital allocation to prioritize and invest in high conviction opportunities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ben Taylor
CEO President
CFO President
Chief Medical
Director Vicki
Goodman Chief
Medical Officer
Officer Ben
President Director
President Recursion
Recursion UK
Taylor CFO
UK EDT
Vicki Goodman
RXRX Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call summary highlights a commitment to AI-driven innovation and financial discipline, which are positives, but lacks specific financial details such as revenue or margin figures. The Q&A section does not provide additional insights, and risks related to AI development and regulatory compliance are noted. With a market cap of approximately $1.8 billion, the absence of explicit financial metrics and shareholder return plans suggests a neutral stock price movement in the short term.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Neutral4-17
RXRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
